AR082726A1 - Derivados de triazolopirazina - Google Patents

Derivados de triazolopirazina

Info

Publication number
AR082726A1
AR082726A1 ARP110103111A AR082726A1 AR 082726 A1 AR082726 A1 AR 082726A1 AR P110103111 A ARP110103111 A AR P110103111A AR 082726 A1 AR082726 A1 AR 082726A1
Authority
AR
Argentina
Prior art keywords
denotes
mono
nhet3
hal
nna2
Prior art date
Application number
Other languages
English (en)
Inventor
Brian Hodous
Pomel Vincent Prof
Dominique Swinnen
Horacido Comas
Pascale Gaillard
Deutsch Carl Dr
Burgdorf Lars Dr
Schultz Melanie Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR082726A1 publication Critical patent/AR082726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Son inhibidores de Syk y se pueden emplear, entre otros, para el tratamiento de artritis reumatoidea. Composición farmacéutica, proceso de preparación.Reivindicación 1: Compuestos de la fórmula (1) en donde R1 denota Ar1 o Het1; R2 denota Ar2, Het2, NH(CH2)nAr2, O(CH2)nAr2, NR3(CH2)nHet2, A, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, NHCyc o NH(CH2)pNA2; Ar1 denota fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido con Hal, A, Alk, (CH2)nOH, (CH2)nOA, (CH2)nCOOH, (CH2)nCOOA, SO2A, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, [C(R3)2]nCN, NO2, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONA2, SO2NH2, SO2NHA, SO2NA2, NHCONH2, NHCOA, NHCOAIk, NHCOCH=CH(CH2)pNA2, CHO, COA, SO3H, O(CH2)pNH2, O(CH2)pNHA, O(CH2)pNA2, COHet3, S(CH2)nHet3, (CH2)nHet3 y/o O(CH2)nHet3; Ar2 denota fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido con Hal, A, (CH2)nOH, (CH2)nOA, OAr3, benciloxi, (CH2)nCOOH, (CH2)nCOOA, SO2A, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, [C(R3)2]nCN, NO2, CONH(CH2)pNH2, CONH(CH2)pNHA, CONH(CH2)pNA2, CONH(CH2)pOA, CONH(CH2)pOH, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONA2, SO2NH2, SO2NHA, SO2NA2, OSO2A, NHCONH2, NHCOA, CHO, COA, SO3H, O(CH2)pNH2, O(CH2)pNHA, O(CH2)pNA2, CONHAr3, NHCOAr3, CONHHet3, NHCOHet3, NHSO2A, COHet3, (CH2)nHet3, S(CH2)nHet3 y/o O(CH2)nHet3; Het1 denota un heterociclo insaturado o aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que está mono-, di-, tri- o tetrasustituido con A, OH, OA, Hal, (CH2)nAr3 y/u =O; Het2 denota un heterociclo saturado, insaturado o aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que está mono-, di-, tri- o tetrasustituido con Hal, A, (CH2)nCOOH, (CH2)nCOOA, CHO, COA, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, CN, (CH2)nOH, (CH2)nOA, (CH2)nAr3, (CH2)nHet3, NHSO2A, NASO2A, SO2A, SO2A y/u =O; Het3 denota un heterociclo saturado, insaturado o aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que está mono-, di-, tri- o tetrasustituido con A, Hal, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, (CH2)nOH, (CH2)nOA, COOA, Ar3 y/u =O; R3 denota H o alquilo C1-4; A denota alquilo C1-10 no ramificado o ramificado, en donde 1 - 7 átomos de H pueden estar reemplazados por F y/o en donde uno o dos grupos no adyacentes CH2 pueden estar reemplazados por O, NH, S, SO, SO2 y/o por grupos CH=CH, o alquilo cíclico C3-7; Cyc denota alquilo cíclico C3-7, que puede no estar sustituido o que puede estar monosustituido con NH2; Alk denota alquenilo o alquinilo C2-6; Ar3 denota fenilo, que no está sustituido o que está mono-, di- o trisustituido con Hal y/o A; Hal denota F, Cl, Br o I; n denota 0, 1, 2, 3 ó 4; p denota 1, 2, 3 ó 4; y sus solvatos, sales, tautómeros y estereoisómeros farmacéuticamente aceptables, que incluyen sus mezclas en todas las proporciones.
ARP110103111 2010-08-27 2011-08-26 Derivados de triazolopirazina AR082726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10008927 2010-08-27

Publications (1)

Publication Number Publication Date
AR082726A1 true AR082726A1 (es) 2012-12-26

Family

ID=44629489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103111 AR082726A1 (es) 2010-08-27 2011-08-26 Derivados de triazolopirazina

Country Status (15)

Country Link
US (1) US9023851B2 (es)
EP (1) EP2609098B1 (es)
JP (1) JP5951610B2 (es)
KR (1) KR20130110163A (es)
CN (1) CN103068828B (es)
AR (1) AR082726A1 (es)
AU (1) AU2011295440B2 (es)
BR (1) BR112013004517A2 (es)
CA (1) CA2809331C (es)
EA (1) EA201300282A1 (es)
ES (1) ES2614128T3 (es)
IL (1) IL224869A (es)
MX (1) MX2013002198A (es)
SG (1) SG188296A1 (es)
WO (1) WO2012025186A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114557B (zh) * 2012-02-21 2017-10-24 默克专利股份公司 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
WO2013131609A1 (en) * 2012-03-07 2013-09-12 Merck Patent Gmbh Triazolopyrazine derivatives
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
CN104640850A (zh) * 2012-10-26 2015-05-20 霍夫曼-拉罗奇有限公司 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂
CA2903901A1 (en) * 2013-03-05 2014-09-12 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
EP2964649B1 (en) * 2013-03-05 2017-05-10 Merck Patent GmbH Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
CN105164136B (zh) * 2013-05-06 2017-12-22 默克专利股份公司 作为激酶抑制剂的大环化合物
US10821178B2 (en) 2013-07-29 2020-11-03 Board Of Regents Of The University Of Nebraska Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR101756934B1 (ko) 2014-07-08 2017-07-12 연세대학교 산학협력단 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물
IL292677A (en) 2016-12-22 2022-07-01 Calithera Biosciences Inc Preparations and methods for inhibiting arginase activity
TW202000666A (zh) 2018-02-27 2020-01-01 美商英塞特公司 作為a2a/a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022002118A1 (zh) * 2020-07-01 2022-01-06 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420883T1 (de) * 2005-02-03 2009-01-15 Vertex Pharma Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
JP4652906B2 (ja) * 2005-06-30 2011-03-16 富士夫 宮脇 振動型マイクロインジェクション装置
US8012966B2 (en) * 2006-01-27 2011-09-06 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
EP2081936B1 (en) * 2006-11-03 2014-04-02 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
MX2010014005A (es) 2008-06-20 2011-02-15 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
KR20110031475A (ko) 2008-06-20 2011-03-28 제넨테크, 인크. 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US8501936B2 (en) * 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
BR112012017310A2 (pt) * 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators

Also Published As

Publication number Publication date
CA2809331A1 (en) 2012-03-01
CA2809331C (en) 2018-09-25
EA201300282A1 (ru) 2013-08-30
CN103068828A (zh) 2013-04-24
JP5951610B2 (ja) 2016-07-13
IL224869A (en) 2016-06-30
BR112013004517A2 (pt) 2016-06-07
SG188296A1 (en) 2013-04-30
KR20130110163A (ko) 2013-10-08
MX2013002198A (es) 2013-03-18
US20130225568A1 (en) 2013-08-29
JP2013538214A (ja) 2013-10-10
AU2011295440B2 (en) 2015-06-11
US9023851B2 (en) 2015-05-05
AU2011295440A1 (en) 2013-04-11
EP2609098B1 (en) 2016-07-13
CN103068828B (zh) 2015-09-09
ES2614128T3 (es) 2017-05-29
EP2609098A1 (en) 2013-07-03
WO2012025186A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
AR082726A1 (es) Derivados de triazolopirazina
AR082727A1 (es) Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen
AR078313A1 (es) Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras
AR082722A1 (es) Derivados de pirimidina
AR067506A1 (es) Derivados de quinazolinamida
ES2587953T3 (es) Amidas cíclicas como inhibidores de MetAP-2
AR092365A1 (es) Derivados de piridopirimidina
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR096235A1 (es) Arilquinazolinas
AR083402A1 (es) Pirrolidinonas como inhibidores de metap-2
AR068658A1 (es) Derivados de tiazol
AR082728A1 (es) Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos
AR055376A1 (es) Derivados de 1-acildihidropirazol
AR082109A1 (es) Derivados de bipiridilo
AR057214A1 (es) Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.
AR082414A1 (es) Carboxamidas azaheterociclicas biciclicas utiles para tratar enfermedades hiperproliferativas e inflamatorias, composiciones farmaceuticas que las contienen y procedimiento para prepararlas
AR066543A1 (es) Derivados de piridazinona
AR072792A1 (es) DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS
AR084507A1 (es) Derivados de indazoliltriazol
AR066770A1 (es) Derivados de piridazinona
AR068657A1 (es) Derivados de piperidina y piperazina
AR054047A1 (es) Derivados de fenilquinazolina
AR068659A1 (es) Derivados de imidazol inhibidores de autotaxina
AR074418A1 (es) Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR

Legal Events

Date Code Title Description
FB Suspension of granting procedure